Skip to main content

Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.

Publication ,  Journal Article
Chen, G; Xu, J; Luo, H; Luo, X; Singh, SK; Ramirez, JJ; James, ML; Mathew, JP; Berger, M; Eroglu, C; Ji, R-R
Published in: JCI Insight
December 8, 2022

High endothelial venule protein/SPARC-like 1 (hevin/Sparcl1) is an astrocyte-secreted protein that regulates synapse formation in the brain. Here we show that astrocytic hevin signaling plays a critical role in maintaining chronic pain. Compared with WT mice, hevin-null mice exhibited normal mechanical and heat sensitivity but reduced inflammatory pain. Interestingly, hevin-null mice have faster recovery than WT mice from neuropathic pain after nerve injury. Intrathecal injection of WT hevin was sufficient to induce persistent mechanical allodynia in naive mice. In hevin-null mice with nerve injury, adeno-associated-virus-mediated (AAV-mediated) re-expression of hevin in glial fibrillary acidic protein-expressing (GFAP-expressing) spinal cord astrocytes could reinstate neuropathic pain. Mechanistically, hevin is crucial for spinal cord NMDA receptor (NMDAR) signaling. Hevin-potentiated N-Methyl-D-aspartic acid (NMDA) currents are mediated by GluN2B-containing NMDARs. Furthermore, intrathecal injection of a neutralizing Ab against hevin alleviated acute and persistent inflammatory pain, postoperative pain, and neuropathic pain. Secreted hevin that was detected in mouse cerebrospinal fluid (CSF) and nerve injury significantly increased CSF hevin abundance. Finally, neurosurgery caused rapid and substantial increases in SPARCL1/HEVIN levels in human CSF. Collectively, our findings support a critical role of hevin and astrocytes in the maintenance of chronic pain. Neutralizing of secreted hevin with monoclonal Ab may provide a new therapeutic strategy for treating acute and chronic pain and NMDAR-medicated neurodegeneration.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCI Insight

DOI

EISSN

2379-3708

Publication Date

December 8, 2022

Volume

7

Issue

23

Location

United States

Related Subject Headings

  • Spinal Cord
  • Receptors, N-Methyl-D-Aspartate
  • Neuralgia
  • Mice
  • Humans
  • Extracellular Matrix Proteins
  • Chronic Pain
  • Calcium-Binding Proteins
  • Animals
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chen, G., Xu, J., Luo, H., Luo, X., Singh, S. K., Ramirez, J. J., … Ji, R.-R. (2022). Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling. JCI Insight, 7(23). https://doi.org/10.1172/jci.insight.161028
Chen, Gang, Jing Xu, Hao Luo, Xin Luo, Sandeep K. Singh, Juan J. Ramirez, Michael L. James, et al. “Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.JCI Insight 7, no. 23 (December 8, 2022). https://doi.org/10.1172/jci.insight.161028.
Chen G, Xu J, Luo H, Luo X, Singh SK, Ramirez JJ, et al. Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling. JCI Insight. 2022 Dec 8;7(23).
Chen, Gang, et al. “Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling.JCI Insight, vol. 7, no. 23, Dec. 2022. Pubmed, doi:10.1172/jci.insight.161028.
Chen G, Xu J, Luo H, Luo X, Singh SK, Ramirez JJ, James ML, Mathew JP, Berger M, Eroglu C, Ji R-R. Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling. JCI Insight. 2022 Dec 8;7(23).

Published In

JCI Insight

DOI

EISSN

2379-3708

Publication Date

December 8, 2022

Volume

7

Issue

23

Location

United States

Related Subject Headings

  • Spinal Cord
  • Receptors, N-Methyl-D-Aspartate
  • Neuralgia
  • Mice
  • Humans
  • Extracellular Matrix Proteins
  • Chronic Pain
  • Calcium-Binding Proteins
  • Animals
  • 42 Health sciences